Elraglusib Combination Therapy Prolongs Survival in Metastatic Pancreatic Cancer

A phase 2 trial published in Nature Medicine on April 14, 2026, found that combining elraglusib with standard chemotherapy prolonged overall survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

Elraglusib is a cell-permeable ATP-competitive inhibitor of glycogen synthase kinase-3β (GSK-3β). The study assessed the efficacy and safety of adding this inhibitor to a chemotherapy regimen consisting of gemcitabine plus nab-paclitaxel, referred to as GnP.

Trial Design and Patient Population

The open-label, international, multicenter study, identified as Part 3B of the phase 2 1801 trial (NCT03678883), randomized patients in a 2:1 ratio. The modified intention-to-treat population consisted of 155 patients receiving elraglusib combined with GnP and 78 patients receiving GnP alone.

Eligible participants were at least 18 years old with measurable disease who had not previously received systematic therapy for their metastatic disease. The trial did not exclude patients based on low albumin levels, high carbohydrate antigen (CA) 19-9 levels, or minimum life expectancy.

Patients in the combination arm received elraglusib at a dose of 9.3 mg/kg, administered either weekly or twice weekly, alongside a 28-day cycle of gemcitabine and nab-paclitaxel.

The mean age of patients was 65.1 years in the elraglusib group, and 66.2 years in the GnP-only group. Both groups were comparable regarding performance status, sites of disease, and baseline CA 19-9 levels, and just over half of the participants in both arms were male.

Survival Outcomes

The primary endpoints of the trial were the 1-year survival rate and median overall survival (OS). Based on a data cutoff of April 27, 2025, the combination of elraglusib and GnP improved median OS to 10.1 months, compared to 7.2 months for those receiving GnP alone.

This represents a 2.9-month improvement in median overall survival. The combination treatment decreased the risk of death by 38% versus the chemotherapy-only arm, with a hazard ratio of 0.62 (95% confidence interval 0.46 to 0.84; P = 0.01).

The 1-year survival rates were also notably different between the two groups. The survival rate at 12 months was 44.1% for patients treated with elraglusib and GnP, compared to 22.3% for those treated with GnP alone.

Safety and Adverse Events

Researchers described the safety profile of the elraglusib and GnP combination as manageable. However, the trial recorded several treatment-emergent adverse events (TEAEs) of grade 3 or higher.

• Neutropenia occurred in 52.3% of the elraglusib/GnP group compared to 30.8% in the GnP group.
• Anemia was reported in 25.2% of the combination group and 29.5% of the GnP group.
• Fatigue affected 16.8% of patients receiving the combination therapy, compared to 5.1% of those receiving GnP alone.

Biological Mechanism and Biomarkers

The study included explorative correlative analyses to understand the biological context of the survival benefit. Findings indicated that the treatment led to increases in intratumoral cytotoxic immune cell populations.

the researchers found that specific baseline circulating immune-related factors were associated with improved survival outcomes in the arm receiving the elraglusib combination. These factors included TRAIL ligands and CXCL2.

Clinical Perspective

The results were presented at the ASCO Gastrointestinal Cancers Symposium in January 2026. Devalingam Mahalingam, MD, PhD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, noted the implications of the findings.

Given the context that this is a randomized clinical trial, our study had a survival meaningful benefit and lays the foundation for GSK-3beta inhibition in subsequent studies in pancreatic cancer, along with other tumor types

Devalingam Mahalingam, MD, PhD